Anthony Elias MDProfessor, Medicine-Medical Oncology, University of Colorado Denver, School of Medicine, Division of Medical Oncology, Aurora, Colorado
My focus has been on experimental therapeutics for breast cancer (BC), describing molecular changes associated with anti-estrogen and/or chemotherapy drug resistance using collaborations with a number of research laboratories, and tissue banking for BC. Another interest is experimental therapy for sarcomas.
Dr. Elias is focused on clinical breast cancer research and is the director of the clinical breast oncology program. This comprehensive program includes a full service Breast Center, including multi-disciplinary clinic and tumor board, a hereditary clinic, benign breast clinic, a screening and breast imaging program, in addition to daily breast specialty oncology clinics. The sarcoma program includes consultation and new patient longitudinal care. Dr. Elias is the principal investigator on numerous national and local therapeutic trials. He is the recipient of the 2013 DOD CTRA on the role of androgen receptor in breast cancer and is institution PI for the Lead Academic Partnership Site (LAPS) grant. He is a member of the SWOG breast and experimental therapeutics committees.
Weitzel L-R B, Byers T, Allen J, et al. Discovery and verification of protein differences between ER positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue. Breast Can Res Ther 2010; Jan 20 (epub). PMID: 2087651
Kabos P, Haughian JM, Wang X, et al. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat 2010; 128: 45-55. Jul 28. Epub ahead of print. PMID: 20665103
Cochrane DR, Cittelly DM, Howe EH, et al.MicroRNAs Link Estrogen Receptor alpha Status and Dicer Level in Breast Cancer. Hormones and Cancer 2011; 1: 306-319. PMID: 21761362
Morrow PK, Murthy FK, Ensor JE, et al. An open-label, phase II trial of Angiozyme (RPI.4610) in the treatment of metastatic breast cancer. Cancer 2012 Jan 26, epub ahead of print.
Kabos P, Finlay-Schultz J, Li C, et al. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat 2012, epub 7/24.
Kessler ER, Elias AD. Resistance to HER2-targeted therapy in HER2+ breast cancer. Clinical Medicine Reviews in Women’s Health, Libertas Academica, 2012, in press.
Modi S, Elias A, LoRusso PM, et al. Results from a dose-escalation study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in patients with HER2-positive MBC previously treated with a trastuzumab-containing regimen. ASCO 2012, accepted.
Elias A, Richer JK, LoRusso P, et al. MDV3100-08: A phase 1 open-label, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of MDV3100 in women with incurable breast cancer. ASCO 2012, accepted.
Dr. Elias has disclosed a financial relationship with the following entities: NCI, DOD, SWOG, Genentech, and Medivation